354 related articles for article (PubMed ID: 25144265)
61. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.
Sorbe BG; Berglind AM; Andersson H; Boman K; Högberg T; Hallgren M; Schmidt M
Cancer; 1998 Sep; 83(5):1022-32. PubMed ID: 9731907
[TBL] [Abstract][Full Text] [Related]
62. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
63. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
[TBL] [Abstract][Full Text] [Related]
64. Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.
Mirabile A; Celio L; Magni M; Bonizzoni E; Gianni AM; Di Nicola M
Future Oncol; 2014 Dec; 10(16):2569-78. PubMed ID: 24947121
[TBL] [Abstract][Full Text] [Related]
65. Antiemetic prophylaxis for chemoradiotherapy-induced nausea and vomiting in locally advanced head and neck squamous cell carcinoma: a prospective phase II trial.
Wang Z; Liu W; Zhang J; Chen X; Wang J; Wang K; Qu Y; Huang X; Luo J; Xiao J; Xu G; Gao L; Yi J; Zhang Y
Strahlenther Onkol; 2022 Oct; 198(10):949-957. PubMed ID: 35635557
[TBL] [Abstract][Full Text] [Related]
66. A randomized double blind study to evaluate efficacy of palonosetron with dexamethasone versus palonosetron alone for prevention of postoperative and postdischarge nausea and vomiting in subjects undergoing laparoscopic surgeries with high emetogenic risk.
Blitz JD; Haile M; Kline R; Franco L; Didehvar S; Pachter HL; Newman E; Bekker A
Am J Ther; 2012 Sep; 19(5):324-9. PubMed ID: 21519222
[TBL] [Abstract][Full Text] [Related]
67. Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer.
Pacetti U; Veltri E; Fattoruso SI; Cardillo FD; Evangelista S; Cognetti F; Fabi A
Anticancer Res; 2013 Apr; 33(4):1721-4. PubMed ID: 23564822
[TBL] [Abstract][Full Text] [Related]
68. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.
Yanai T; Iwasa S; Hashimoto H; Ohyanagi F; Takiguchi T; Takeda K; Nakao M; Sakai H; Nakayama T; Minato K; Arai T; Suzuki K; Shimada Y; Nagashima K; Terakado H; Yamamoto N
Int J Clin Oncol; 2018 Apr; 23(2):382-388. PubMed ID: 29039073
[TBL] [Abstract][Full Text] [Related]
69. Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer.
Fujiwara S; Terai Y; Tsunetoh S; Sasaki H; Kanemura M; Ohmichi M
J Gynecol Oncol; 2015 Oct; 26(4):311-9. PubMed ID: 26197776
[TBL] [Abstract][Full Text] [Related]
70. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation.
Giralt SA; Mangan KF; Maziarz RT; Bubalo JS; Beveridge R; Hurd DD; Mendoza FL; Rubenstein EB; DeGroot TJ; Schuster MW
Ann Oncol; 2011 Apr; 22(4):939-946. PubMed ID: 20935058
[TBL] [Abstract][Full Text] [Related]
71. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
72. Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT.
Musso M; Scalone R; Crescimanno A; Bonanno V; Polizzi V; Porretto F; Bianchini C; Perrone T
Bone Marrow Transplant; 2010 Jan; 45(1):123-7. PubMed ID: 19483762
[TBL] [Abstract][Full Text] [Related]
73. A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Pielichowski W; Barzal J; Gawronski K; Mlot B; Oborska S; Wasko-Grabowska A; Rzepecki P
Transplant Proc; 2011 Oct; 43(8):3107-10. PubMed ID: 21996238
[TBL] [Abstract][Full Text] [Related]
74. Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.
Affronti ML; Schneider SM; Herndon JE; Schlundt S; Friedman HS
Support Care Cancer; 2014 Jul; 22(7):1897-905. PubMed ID: 24570103
[TBL] [Abstract][Full Text] [Related]
75. Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65 years) fit for cisplatin: A sub-analysis from a phase 3 study.
Celio L; Bartsch R; Aapro M
J Geriatr Oncol; 2023 Jul; 14(6):101537. PubMed ID: 37290207
[TBL] [Abstract][Full Text] [Related]
76. Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation.
Yeh SP; Lo WC; Hsieh CY; Bai LY; Lin CC; Lin PH; Lin CY; Liao YM; Chiu CF
Support Care Cancer; 2014 May; 22(5):1199-206. PubMed ID: 24317849
[TBL] [Abstract][Full Text] [Related]
77. New treatments on the horizon for chemoradiotherapy-induced nausea and vomiting.
Ruhlmann CH; Herrstedt J
Expert Opin Pharmacother; 2016 Aug; 17(12):1623-9. PubMed ID: 27322893
[TBL] [Abstract][Full Text] [Related]
78. Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy.
Roscoe JA; Heckler CE; Morrow GR; Mohile SG; Dakhil SR; Wade JL; Kuebler JP
J Clin Oncol; 2012 Sep; 30(27):3389-95. PubMed ID: 22915657
[TBL] [Abstract][Full Text] [Related]
79. Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
Basch E; Prestrud AA; Hesketh PJ; Kris MG; Feyer PC; Somerfield MR; Chesney M; Clark-Snow RA; Flaherty AM; Freundlich B; Morrow G; Rao KV; Schwartz RN; Lyman GH;
J Clin Oncol; 2011 Nov; 29(31):4189-98. PubMed ID: 21947834
[TBL] [Abstract][Full Text] [Related]
80. Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study.
Celio L; Cortinovis D; Cogoni AA; Cavanna L; Martelli O; Carnio S; Collovà E; Bertolini F; Petrelli F; Cassano A; Chiari R; Zanelli F; Pisconti S; Vittimberga I; Letizia A; Misino A; Gernone A; Bonizzoni E; Pilotto S; De Placido S; Bria E
BMC Cancer; 2022 Aug; 22(1):915. PubMed ID: 35999527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
